J&J re­ports sec­ond HIV vac­cine reg­i­men fail­ure in 18 months

Af­ter more than four decades, there is still no ap­proved HIV vac­cine. And an­oth­er so-called mo­sa­ic reg­i­men has end­ed in dis­ap­point­ment.

John­son & John­son’s Janssen unit said Wednes­day that an in­de­pen­dent da­ta and safe­ty mon­i­tor­ing team found the Big Phar­ma’s reg­i­men to be in­ef­fec­tive at pre­vent­ing HIV in­fec­tion com­pared to place­bo. The drug de­vel­op­er re­port­ed no safe­ty is­sues.

With that, J&J end­ed the Phase III Mo­saico study, which en­rolled 3,900 cis­gen­der men and trans­gen­der in­di­vid­u­als in Ar­genti­na, Brazil, Italy, Mex­i­co, Pe­ru, Poland, Puer­to Ri­co, Spain and the US. Peo­ple in the tri­al who con­tract­ed the virus were giv­en “prompt HIV treat­ment and care,” the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.